• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实验室自行开发的检测方法——SynFRAME:一种基于先前评估框架综合评估实验室自行开发检测方法的途径。

Laboratory-developed test--SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks.

作者信息

Hornberger John, Doberne Julie, Chien Rebecca

机构信息

Cedar Associates LLC, Menlo Park, California 94025, USA.

出版信息

Genet Test Mol Biomarkers. 2012 Jun;16(6):605-14. doi: 10.1089/gtmb.2011.0177. Epub 2012 Feb 2.

DOI:10.1089/gtmb.2011.0177
PMID:22300513
Abstract

Since the late 1990 s, there has been an unprecedented growth in the development of new molecular and proteomic assays for clinical decision making. Despite the thousands of tests available, a standardized, well-defined, and coherent evaluation framework for these molecular assays is still lacking. We aim to summarize the publicly available appraisal criteria and to develop a succinct and accessible set of criteria that can provide a roadmap for the appraisal of gene-based laboratory developed tests (LDTs). We conducted a systematic literature review of the available molecular diagnostic framework in PubMed MD and CINAHL and identified 91 articles on existing appraisal criteria. We provided a summary of the historical appraisal system and developed an analysis of these appraisal systems, LDT-SynFRAME, which details the major criteria for evaluating molecular diagnostics in the clinical setting. Our goal with the LDT-SynFRAME system is to promote a well-informed dialog among all the stakeholders responsible for the development, approval, reimbursement, and use of new molecular classifiers.

摘要

自20世纪90年代末以来,用于临床决策的新型分子和蛋白质组学检测方法的开发取得了前所未有的增长。尽管有数千种检测方法可供使用,但这些分子检测方法仍缺乏一个标准化、定义明确且连贯的评估框架。我们旨在总结公开可用的评估标准,并制定一套简洁易懂的标准,为基于基因的实验室开发检测方法(LDT)的评估提供路线图。我们对PubMed MD和CINAHL中可用的分子诊断框架进行了系统的文献综述,共识别出91篇关于现有评估标准的文章。我们总结了历史评估系统,并对这些评估系统进行了分析,开发了LDT-SynFRAME,该系统详细阐述了临床环境中评估分子诊断的主要标准。我们使用LDT-SynFRAME系统的目标是促进所有负责新分子分类器开发、批准、报销和使用的利益相关者之间进行明智的对话。

相似文献

1
Laboratory-developed test--SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks.实验室自行开发的检测方法——SynFRAME:一种基于先前评估框架综合评估实验室自行开发检测方法的途径。
Genet Test Mol Biomarkers. 2012 Jun;16(6):605-14. doi: 10.1089/gtmb.2011.0177. Epub 2012 Feb 2.
2
The Health Technology Assessment of companion diagnostics: experience of NICE.伴随诊断的卫生技术评估:NICE 的经验。
Clin Cancer Res. 2014 Mar 15;20(6):1469-76. doi: 10.1158/1078-0432.CCR-13-1955.
3
Development and description of GETT: a genetic testing evidence tracking tool.发展和描述 GETT:一个基因检测证据跟踪工具。
Clin Chem Lab Med. 2010 Oct;48(10):1397-407. doi: 10.1515/CCLM.2010.291. Epub 2010 Jul 27.
4
Molecular genetic testing in the United States: comparison with international practice.美国的分子基因检测:与国际实践的比较。
Genet Test. 2008 Jun;12(2):187-93. doi: 10.1089/gte.2007.0087.
5
Multi-criteria development and incorporation into decision tools for health technology adoption.多标准制定及其在决策工具中的整合以用于医疗技术的采用。
J Health Organ Manag. 2013;27(2):246-65. doi: 10.1108/14777261311321806.
6
Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array.分子检测性能规格的验证:使用 Luminex 液相芯片技术进行囊性纤维化携带者检测。
Arch Pathol Lab Med. 2012 Jan;136(1):14-9. doi: 10.5858/arpa.2010-0536-OA.
7
An integrated approach to oversight assessment for emerging technologies.新兴技术监督评估的综合方法。
Risk Anal. 2008 Oct;28(5):1197-220. doi: 10.1111/j.1539-6924.2008.01086.x. Epub 2008 Jul 9.
8
Molecular diagnostics in routine practice: quality issues and application to complex disease.常规实践中的分子诊断:质量问题及在复杂疾病中的应用
Ann Clin Biochem. 2003 Jul;40(Pt 4):309-12. doi: 10.1258/000456303766476959.
9
Genetic tests and their evaluation: can we answer the key questions?基因检测及其评估:我们能回答关键问题吗?
Genet Med. 2004 Nov-Dec;6(6):475-80. doi: 10.1097/01.gim.0000144060.84960.36.
10
Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories.《下一代测序技术在基因组诊断应用中的最佳实践指南:荷兰基因组诊断实验室的国家合作研究》。
Hum Mutat. 2013 Oct;34(10):1313-21. doi: 10.1002/humu.22368. Epub 2013 Aug 19.

引用本文的文献

1
A Systematic Review and Recommendations Around Frameworks for Evaluating Scientific Validity in Nutritional Genomics.关于营养基因组学中科学有效性评估框架的系统评价与建议
Front Nutr. 2021 Dec 14;8:789215. doi: 10.3389/fnut.2021.789215. eCollection 2021.
2
A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies.系统评价在组学技术卫生技术评估中使用的价值评估框架及其在 HTA 机构中的实际应用。
Int J Environ Res Public Health. 2020 Oct 30;17(21):8001. doi: 10.3390/ijerph17218001.
3
A proposal of a new evaluation framework towards implementation of genetic tests.
一种新的遗传检测实施评估框架的建议
PLoS One. 2019 Aug 5;14(8):e0219755. doi: 10.1371/journal.pone.0219755. eCollection 2019.
4
How is genetic testing evaluated? A systematic review of the literature.遗传检测如何评估?文献系统评价。
Eur J Hum Genet. 2018 May;26(5):605-615. doi: 10.1038/s41431-018-0095-5. Epub 2018 Feb 8.
5
Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies.组合药物基因组学指导的抗抑郁治疗的临床效用:来自三项临床研究的证据
Mol Neuropsychiatry. 2015 Oct;1(3):145-55. doi: 10.1159/000430915. Epub 2015 Jul 31.
6
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.日本雌激素受体阳性、淋巴结阴性早期乳腺癌21基因检测的社会成本效益分析。
BMC Health Serv Res. 2014 Sep 5;14:372. doi: 10.1186/1472-6963-14-372.
7
Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.基因组分类器检测对高危前列腺癌术后患者临床实践决策的影响。
BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789. Epub 2014 Aug 11.
8
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.转移风险基因组分类器对前列腺癌患者术后治疗建议的影响:DECIDE研究组报告
Oncotarget. 2013 Apr;4(4):600-9. doi: 10.18632/oncotarget.918.
9
Evaluating genomic tests from bench to bedside: a practical framework.从实验室到临床评估基因组检测:一个实用框架。
BMC Med Inform Decis Mak. 2012 Oct 19;12:117. doi: 10.1186/1472-6947-12-117.